• Franz H Messerli, Sripal Bangalore, Chirag Bavishi, and Stefano F Rimoldi.
• Department of Cardiology and Clinical Research, University Hospital, Bern, Switzerland; Division of Cardiology, Mount Sinai Medical Center, Icahn School of Medicine, New York, New York. Electronic address: messerli.f@gmail.com.
• J. Am. Coll. Cardiol. 2018 Apr 3; 71 (13): 1474-1482.

AbstractMost guidelines for the management of patients with cardiovascular disease recommend angiotensin-converting enzyme (ACE) inhibitors as first-choice therapy, whereas angiotensin receptor blockers (ARBs) are merely considered an alternative for ACE inhibitor-intolerant patients. The aim of this review was to compare outcomes and adverse events between ACE inhibitors and ARBs in patients. In patients with hypertension and hypertension with compelling indications, we found no difference in efficacy between ARBs and ACE inhibitors with regard to the surrogate endpoint of blood pressure and outcomes of all-cause mortality, cardiovascular mortality, myocardial infarction, heart failure, stroke, and end-stage renal disease. However, ACE inhibitors remain associated with cough and a very low risk of angioedema and fatalities. Overall withdrawal rates because of adverse events are lower with ARBs than with ACE inhibitors. Given the equal outcome efficacy but fewer adverse events with ARBs, risk-to-benefit analysis in aggregate indicates that at present there is little, if any, reason to use ACE inhibitors for the treatment of hypertension or its compelling indications.Copyright © 2018 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

39 keywords...

hide…